Immuron Files Pre-IND Application For IMM-529 - Quick Facts
(RTTNews) - Immuron (IMRN) said it has filed a pre-IND application with the FDA for IMM-529. The company is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection.
Immuron is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It is collaborating with Dena Lyras and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.